PT  - JOURNAL ARTICLE
AU  - Klann, Eric
TI  - Thwarting Dyskinesia by Targeting mTORC1
AID  - 10.1126/scisignal.280pe42
DP  - 2009 Jul 21
TA  - Science Signaling
PG  - pe42--pe42
VI  - 2
IP  - 80
4099  - http://stke.sciencemag.org/content/2/80/pe42.short
4100  - http://stke.sciencemag.org/content/2/80/pe42.full
SO  - Sci. Signal.2009 Jul 21; 2
AB  - In a mouse model of Parkinson’s disease, new evidence shows that l-DOPA, which is used to treat the symptoms of the disease but also causes dyskinesia, results in a persistent activation of the protein kinase mTOR (mammalian target of rapamycin) in a subset of striatal medium spiny neurons. Moreover, blockade of a specific type of mTOR signaling (mTORC1) prevents the development of dyskinesia, but not the antiakinetic benefits produced by l-DOPA. Thus, mTORC1 may be a viable therapeutic target for dyskinesia caused by l-DOPA treatment in patients with Parkinson’s disease.